Printer Friendly Version View printer-friendly version
<< Back
Array BioPharma To Hold Conference Call To Discuss Clinical Data Presentations In Melanoma And Colorectal Cancer On September 28, 2015

BOULDER, Colo., Sept. 25, 2015 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq:  ARRY) will hold a conference call to discuss preliminary results from two melanoma trials and a colorectal cancer trial on Monday, September 28, 2015.  Ron Squarer, Chief Executive Officer, and Victor Sandor, M.D., Chief Medical Officer, will lead the call.

Array BioPharma

The trials include a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2), a Phase 1b/2 combination trial of binimetinib and a CDK4/6 inhibitor in NRAS-mutant melanoma patients and a Phase 2 combination trial of encorafenib and an EGFR inhibitor with or without the addition of a PI3K inhibitor in patients with BRAF-mutant colorectal cancer.  Data from these trials will be presented at the European Society of Medical Oncology's (ESMO) annual European Cancer Conference (ECC) or were presented at the 2015 ESMO World Congress of Gastrointestinal Cancer.

Conference Call Information


Monday, September 28, 2015


9:00 a.m. eastern time


(844) 464-3927


(765) 507-2598

Pass Code:


Webcast, including Replay and Conference Call Slides:

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Six registration studies are currently advancing related to three cancer drugs. These programs include binimetinib (MEK162 / wholly-owned), encorafenib (LGX818 / wholly-owned) and selumetinib (AstraZeneca). For more information on Array, please go to


Tricia Haugeto

Array BioPharma Inc.

(303) 386-1193

 Logo -


To view the original version on PR Newswire, visit:

SOURCE Array BioPharma